Newer antibacterials in therapy and clinical trials

North American Journal of Medical Sciences

Volumn 4, Issue 11, 2012, Pages 537-547

  Paknikar, Simi S ^a   Narayana, Sarala ^a  

^a SRI DEVARAJ URS MEDICAL COLLEGE   (India)

Author keywords

Antibiotic resistance; Latest antibacterials; New antibacterials

Indexed keywords

ANTIINFECTIVE AGENT; BC 3781; BESIFLOXACIN; CEFDITOREN PIVOXIL; CEFTAROLINE; CEFTOBIPROLE; DAPTOMYCIN; DELAFLOXACIN; DORIPENEM; ERTAPENEM; FIDAXOMICIN; FINAFLOXACIN; GEMIFLOXACIN; LINEZOLID; MODITHROMYCIN; NEMONOXACIN; NXL 103; ORITAVANCIN; PRULIFLOXACIN; RADEZOLID; RAMOPLANIN; RAZUPENEM; RETAPAMULIN; STREPTOGRAMIN; SULOPENEM; TEDIZOLID; TELAVANCIN; TELITHROMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZABOFLOXACIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; BONE MARROW SUPPRESSION; CHRONIC BRONCHITIS; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; DIABETIC FOOT; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENTEROCOCCAL INFECTION; HEADACHE; HELICOBACTER INFECTION; HUMAN; LACTIC ACIDOSIS; LIVER TOXICITY; LOOSE FECES; MINIMUM INHIBITORY CONCENTRATION; MYASTHENIA GRAVIS; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; OPTIC NERVE DISEASE; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; SURGICAL INFECTION; TASTE DISORDER; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING;

EID: 84869457133     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.103312     Document Type: Article

References (45)

1. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 2009;325:1089-93.
2. Ryder NS. Discontinued drugs in 2008: Anti-infectives. Expert Opin Investig Drugs 2010;19:1-21.
3. Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 2010;19:215-234.
4. th ed. New York, NY: McGraw Hill Medical; 2011.
5. Manfredi R, Sabbatani S. Novel pharmaceutical molecules against emerging resistant gram- positive cocci. Braz J Infect Dis 2010;14:96-108.
6. Lemaire S, Tulkens PM, Van Bambeke F. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: Studies with macrophages and polymorphonuclear neutrophils. Antimicrob Agents Chemother 2010;54:2540-2548.
7. Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: Studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother 2010;54:2549-2559.
8. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and effcacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55:583-592.
9. Betriu C, Morales G, Rodríguez-Avial I, Culebras E, Gómez M, López-Fabal F, et al. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother 2010;54:2212-2215.
10. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283-288.
11. Politano AD, Sawyer RG NXL-103, a combination of fopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs 2010;11:225-236.
12. Dunbar LM, Tang DM, Manausa RM. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manag 2008;4:235-244.
13. Bonkowski J, Daniels AR, Peppard WJ. Role of telavancin in treatment of skin and skin structure infections. Clin Cosmet Investig Dermatol 2010;3:127-133.
14. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010;30:80-94.
15. Montecalvo MA. Ramoplanin: A novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother 2003;51 Suppl 3:331-335.
16. Moody MN, Morrison LK, Tyring SK. Retapamulin: What is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Therapy Lett 2010;15:1-4.
17. Nabriva Therapeutics presents extended Phase II results for pleuromutilin antibiotic BC-3781. (Accessed December 1, 2011, at http://www.drugs.com/clinical_trials/nabriva_therapeutics_presents_extended_phase_ii_results_pleuromutilin_antibiotic_bc_3781_12362.html).
18. Abbanat D, Morrow B, Bush K. New agents in development for the treatment of bacterial infections. Curr Opin Pharmacol 2008;8:582-592.
19. Saravolatz LD, Leggett J. Gatifoxacin, gemifoxacin, and moxifoxacin: The role of 3 newer fuoroquinolones. Clin Infect Dis 2003;37:1210-1215.
20. Morrissey I, Tillotson G. Activity of gemifoxacin against Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 2004;53:144-148.
21. Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: A novel anti-infective for the treatment of bacterial conjunctivitis. Clin Ophthalmol 2010;4:215-225.
22. TaiGen announces presentation of nemonoxacin at the joint meeting of ICAAC/IDSA. (Accessed December 1, 2001, at http://www.drugs.com/clinical_trials/ aigen_announces_presentation_nemonoxacin_joint_meeting_ icaac_idsa_5844.html).
23. van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, et al. Effcacy and safety of nemonoxacin versus levofoxacin for community-acquired pneumonia. Antimicrob Agents Chemother 2010;54:4098-4106.
24. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H. Activity of the investigational fuoroquinolone fnafoxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother 2010;54:1613-1615.
25. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fuoroquinolone. Antimicrob Agents Chemother 2010;54:1955-1964.
26. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fuoroquinolones moxifoxacin and delafoxacin against Staphylococcus aureus. Antimicrob Agents Chemother 2011;55:649-658.
27. Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L. Prulifoxacin: A brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis 2007;2:27-31.
28. Safety and effcacy study of oral zabofoxacin in community acquired pneumonia. (Accessed December 1, 2011 at http://clinicaltrials.gov/ct2/show/NCT01081964).
29. Barberán J, Mensa J. Cefditoren and community-acquired lower respiratory tract infections. Rev Esp Quimioter 2009;22:144-150.
30. Manaktala C, Singh AK, Verma M, Sachdeva A, Sharma H, Roy A, et al. Effcacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients. Indian J Dermatol 2009;54:350-6.
31. Girish C, Balakrishnan S. Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin. J Pharmacol Pharmacother 2011;2:209-11.
32. Shah PM, Isaacs RD. Ertapenem, the frst of a new group of carbapenems. J Antimicrob Chemother 2003;52:538-42.
33. Wexler HM. In vitro activity of ertapenem: Review of recent studies. J Antimicrob Chemother 2004;53 Suppl 2:211-221.
34. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8.
35. El Solh A. Ceftobiprole: A new broad spectrum cephalosporin. Expert Opin Pharmacother 2009;10:1675-86.
36. Ohlsen K. Novel antibiotics for the treatment of Staphylococcus aureus. Expert Rev Clin Pharmacol 2009;2:661-672.
37. Hamilton-Miller J.M. Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: Focus on faropenem. Pharmacotherapy 2003;23:1497-1507.
38. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
39. Shah D, Dang MD, Hasbun R, Koo HL, Jiang ZD, DuPont HL, et al. Clostridium diffcile infection: Update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010;8:555-564.
40. Rafe S, MacDougall C, James CL. Cethromycin: A promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 2010;30:290-303.
41. Lonks JR, Goldmann D.A. Telithromycin: A ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005;40:16 57-64.
42. Jiang LJ, Or YS. Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study. Antimicrob Agents Chemother 2009;53:3218-3225.
43. Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 2010;54:4961-4970.
44. Seputiene V, Povilonis J, Armalyte J, Suziedelis K, Pavilonis A, Suziedeliene E. Tigecycline - How powerful is it in the fght against antibiotic-resistant bacteria? Medicina (Kaunas) 2010;46:240-248.
45. Neuner EA, Ritchie DJ, Micek ST. New antibiotics for healthcare-associated pneumonia. Semin Respir Crit Care Med 2009;30:92-101.